Stock-punishing news this fall about a slowdown in development of Incyte Corp''s HIV drug was followed by much happier word Monday, in the form of a potential $803 million research and licensing deal with Pfizer Inc. focused on the Phase II CCR2 antagonist program. (BioWorld Today) Read More
